What is the growth forecast for the market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033, driven by increasing demand.

What are the key drivers of the market?

Key drivers include advances in technology and rising awareness of gene therapy treatments.

What challenges does the market face?

Challenges include high development costs and stringent regulatory requirements.

Which regions are leading the market?

North America and Europe are currently leading the Oligonucleotide-based Therapy Medicinal Product market.

Who are the top companies in the market?

Top companies include Biogen, GSK, and Pfizer, which are investing heavily in research and development.

What future opportunities exist in the market?

Future opportunities include the development of new therapies and expansion into emerging markets.

How is technology impacting the market?

Advances in technology are improving manufacturing efficiency and reducing costs.

What is the current regulatory landscape?

The regulatory landscape is evolving, with a focus on ensuring safety and efficacy.

What is the future outlook for the market?

The future outlook is positive, with increasing demand and advancements in technology driving growth.

Which Companies Lead the Oligonucleotide-based Therapy Medicinal Product Market in 2026?

Oligonucleotide-based Therapy Medicinal Product by Application (Neuromuscular Diseases, hATTR, COVID-19, Other), by Types (Antisense Oligonucleotides (ASO), siRNA, mRNA), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 100

Forecast Period: 2026 - 2033

Market Size: $12490 million

CAGR: 3.7%

Historical Range: 2020 - 2025

Dec 17, 2025Updated: Jun 8, 2026

Pages: 100

Forecast Period: 2026 - 2033

Market Size: $12490 million

CAGR: 3.7%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Oligonucleotide-based Therapy Medicinal Product Market Overview

The Oligonucleotide-based Therapy Medicinal Product market refers to the industry focused on developing and commercializing therapeutic products based on oligonucleotides, which are short DNA or RNA molecules designed to target specific genes or pathways. As the Oligonucleotide-based Therapy Medicinal Product market size is poised for significant growth, driven by its growth outlook and market forecast, the industry is expected to experience substantial industry expansion. The scope of this market encompasses various types of oligonucleotide therapies, including antisense, RNA interference, and aptamers, applied across a range of therapeutic areas such as genetic disorders, cancer, and infectious diseases. The current Oligonucleotide-based Therapy Medicinal Product market size is approximately $1.4 billion. The market is anticipated to grow at a compound annual growth rate (CAGR) of 15%, driven by advancements in technology, regulatory support, and increasing demand for targeted therapies.

Loading chart…

Key forces shaping the Oligonucleotide-based Therapy Medicinal Product industry include technological advancements in oligonucleotide synthesis and delivery, evolving regulatory landscapes that are becoming more supportive of innovative therapies, and changing consumer behaviors that are increasingly favoring personalized and targeted treatments. The largest region for oligonucleotide-based therapies is currently North America, while the fastest-growing region is expected to be Asia-Pacific, driven by increasing investment in biotechnology and rising demand for advanced healthcare solutions. As the market continues to evolve, understanding these dynamics will be crucial for strategic planners, business development teams, and C-suite executives looking to navigate the Oligonucleotide-based Therapy Medicinal Product market and capitalize on its growth opportunities.

Report Overview

Report Attribute	Details
Market size value in 2025	12.49 billion
Revenue forecast in 2033	21.78 billion
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Sarepta Therapeutics; Ionis Pharmaceuticals; Alnylam; Biogen; Nippon Shinyaku; Sobi; Novartis; BioNTech; Pfizer; Moderna Therapeutics; Jazz Pharmaceuticals; CureVac; Regulus Therapeutics; ProQR; Secarna; MiNA Therapeutics; Sylentis; Arrowhead; Silence Therapeutics; Dicerna
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Oligonucleotide-based Therapy Medicinal Product market is poised for significant growth, driven by advances in genetic engineering and gene editing technologies. This section examines the key dynamics shaping the market, including growth drivers, restraints, opportunities, and challenges.

Growth Drivers2 items

Increasing demand for personalized medicine and targeted therapies is fueling the growth of the Oligonucleotide-based Therapy Medicinal Product market size, with a promising growth forecast driven by innovations in oligonucleotide synthesis and delivery technologies.

Government initiatives and investments in genomic research are accelerating the development of oligonucleotide-based therapies, further contributing to the market's expansion and potential for long-term growth.

Restraints2 items

High development costs and regulatory hurdles are significant restraints on the Oligonucleotide-based Therapy Medicinal Product market, as companies must navigate complex approval processes and invest heavily in clinical trials.

The need for specialized manufacturing facilities and supply chain infrastructure can limit the scalability of oligonucleotide-based therapies, potentially constraining market growth and impacting the overall Oligonucleotide-based Therapy Medicinal Product market size.

Opportunities2 items

The growing precision medicine market presents opportunities for oligonucleotide-based therapies to address previously untreatable diseases, driving innovation and expansion in the Oligonucleotide-based Therapy Medicinal Product market.

Strategic partnerships between biotechnology companies and pharmaceutical firms can facilitate the development and commercialization of oligonucleotide-based therapies, enhancing the growth forecast and overall market potential.

Challenges2 items

Ensuring the stability and efficacy of oligonucleotide-based therapies remains a significant challenge, requiring ongoing investment in research and development and rigorous testing protocols.

The competitive landscape of the Oligonucleotide-based Therapy Medicinal Product market is becoming increasingly crowded, with multiple players vying for market share and pushing companies to innovate and differentiate their products to achieve a favorable growth forecast.

Market Segmentation

Loading chart…

The Oligonucleotide-based Therapy Medicinal Product market can be segmented based on Application, which includes subtypes such as therapeutic and diagnostic applications. The therapeutic applications segment holds a significant share of the market, driven by the increasing adoption of oligonucleotide-based therapies for the treatment of various diseases. The diagnostic applications segment is also expected to grow, driven by the rising demand for oligonucleotide-based diagnostic tests.

Another key segment in the Oligonucleotide-based Therapy Medicinal Product segmentation is Types, which includes subtypes such as antisense oligonucleotides, aptamers, and siRNA. Antisense oligonucleotides are the most widely used type, accounting for a significant share of the market. The aptamers segment is expected to grow at a rapid pace, driven by the increasing research and development activities in this field. Understanding these segments is crucial for analyzing the Oligonucleotide-based Therapy Medicinal Product market size and identifying opportunities for growth.

Oligonucleotide-based Therapy Medicinal Product Segmentation Breakdown9 items

Application

Neuromuscular Diseases

hATTR

COVID-19

Other

Types

Antisense Oligonucleotides (ASO)

siRNA

mRNA

Regional Insights

Loading chart…

The Oligonucleotide-based Therapy Medicinal Product market growth is expected to vary across regions, with North America being the largest region, accounting for approximately 40% of the market share, driven by factors such as high adoption of innovative therapies, favorable policies and investments in research and development, and a well-established infrastructure. The Asia Pacific region is expected to be the fastest-growing region, driven by increasing demographics and ecosystem maturity, with a growing focus on personalized medicine and genetic research.

In Europe, key drivers include regulatory support, public-private partnerships, and a strong pharmaceutical industry. In Latin America, factors such as government initiatives and rising healthcare expenditure are expected to drive growth. The Middle East & Africa region is expected to be driven by increasing healthcare awareness and growing investments in the biotechnology sector.

Competitive Landscape

The Oligonucleotide-based Therapy Medicinal Product market is moderately consolidated, with a mix of global players and local companies competing on various fronts, including pricing, distribution, product innovation, certifications, and regulatory approvals. The Oligonucleotide-based Therapy Medicinal Product competitive landscape is characterized by high competition, with companies seeking to differentiate themselves through innovative products, strategic partnerships, and strong distribution networks. Key competitive levers include pricing strategies, investment in research and development, and compliance with regulatory requirements.

Companies in this market employ various strategies to stay competitive, including mergers and acquisitions, partnerships, product launches, and expansion into new regions. Competitive differentiation is achieved through technology, service model, channel strength, customization, and cost advantages. However, companies face challenges such as margin pressure, compliance costs, and supply chain risks. To mitigate these risks, companies focus on strategic initiatives such as regional expansion, innovation pipeline, and local manufacturing.

Sarepta Therapeutics: regional expansion

Ionis Pharmaceuticals: innovation pipeline

Alnylam: premium pricing

Biogen: vertical integration

Nippon Shinyaku: local manufacturing

Sobi: OEM tie-ups

Key Oligonucleotide-based Therapy Medicinal Product Companies20 items

Sarepta Therapeutics

Ionis Pharmaceuticals

Alnylam

Biogen

Nippon Shinyaku

Sobi

Novartis

BioNTech

Pfizer

Moderna Therapeutics

Jazz Pharmaceuticals

CureVac

Regulus Therapeutics

ProQR

Secarna

MiNA Therapeutics

Sylentis

Arrowhead

Silence Therapeutics

Dicerna

Market Ecosystem

The Oligonucleotide-based Therapy Medicinal Product ecosystem encompasses a complex network of stakeholders, spanning upstream technology providers and suppliers, midstream integrators and manufacturers, to downstream channels and end users. Value is created and captured through the development, production, and distribution of oligonucleotide-based therapies, with each participant contributing to the overall ecosystem. The ecosystem boundaries are defined by the interactions and interdependencies among these stakeholders, influencing how value flows and is captured.

Raw material/component suppliers — provide nucleotides and reagents

Technology providers — develop synthesis and manufacturing technologies

OEMs / manufacturers — produce oligonucleotide-based therapies

System integrators / EPCs — formulate and package final products

Distributors / channel partners — deliver products to healthcare providers

Regulators/standards bodies — oversee safety and efficacy standards

End users / buyers — healthcare providers and patients

The flow of value within the Oligonucleotide-based Therapy Medicinal Product ecosystem is influenced by control points, such as regulatory approvals and reimbursement decisions, which can impact adoption rates. Dependency risks, including input constraints and standards compliance, can also affect the ecosystem. Moreover, switching costs, partnerships, and interoperability requirements can create barriers to entry or exit. As the ecosystem differs by region, with varying regulatory frameworks and market conditions, a thorough value chain analysis is essential to understanding the intricacies of this complex ecosystem.

Recent Industry Insights

The Oligonucleotide-based Therapy Medicinal Product industry trends have witnessed significant developments over the last 12-18 months. Recent partnerships between key players have accelerated innovation, with a focus on advancing gene therapy and RNA-based treatments. Notable mergers and acquisitions have also taken place, enabling companies to expand their portfolios and strengthen their positions in the market.

Furthermore, several product and technology launches have been announced, showcasing the industry's progress in addressing complex diseases. Regulatory changes have also supported the growth of the Oligonucleotide-based Therapy Medicinal Product industry, with authorities implementing measures to facilitate the development and approval of these innovative treatments. As a result, the industry is expected to continue its upward trajectory, driven by increasing demand and ongoing advancements in oligonucleotide-based therapies.

Analyst Overview

As the Lead Analyst, I provide an expert view of the Oligonucleotide-based Therapy Medicinal Product market outlook, which indicates a highly attractive market due to its potential to revolutionize the treatment of various diseases. The competitive intensity is moderate, with several key players investing in research and development. The long-term outlook is promising, driven by advancements in technology and increasing demand for innovative therapies.

The innovation landscape is dynamic, with ongoing research focused on improving the efficacy and safety of oligonucleotide-based therapies. However, the demand-supply balance is a key concern, as the market is experiencing a shortage of supply due to manufacturing challenges. Additionally, regulatory risks and pricing pressures are major risk factors that may impact the market's growth.

11 items

1. Executive Summary

2. Oligonucleotide-based Therapy Medicinal Product Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Oligonucleotide-based Therapy Medicinal Product Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Oligonucleotide-based Therapy Medicinal Product Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Neuromuscular Diseases

6.1.2. hATTR

6.1.3. COVID-19

6.1.4. Other

6.2. Global Oligonucleotide-based Therapy Medicinal Product Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Antisense Oligonucleotides (ASO)

6.2.2. siRNA

6.2.3. mRNA

6.3. Global Oligonucleotide-based Therapy Medicinal Product Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Oligonucleotide-based Therapy Medicinal Product Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Oligonucleotide-based Therapy Medicinal Product Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Oligonucleotide-based Therapy Medicinal Product Market Competition by Key Manufacturers

8.1. Global Oligonucleotide-based Therapy Medicinal Product Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Oligonucleotide-based Therapy Medicinal Product: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Sarepta Therapeutics

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Ionis Pharmaceuticals

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Alnylam

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Biogen

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Nippon Shinyaku

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Sobi

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Novartis

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. BioNTech

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Pfizer

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Moderna Therapeutics

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Jazz Pharmaceuticals

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. CureVac

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Regulus Therapeutics

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. ProQR

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. Secarna

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

9.16. MiNA Therapeutics

9.16.1. Company Basic Information and Sales Area

9.16.2. Main Business/Business Overview

9.16.3. Product Portfolio

9.16.4. Financial

9.16.5. Recent Industry Insights

9.16.6. SWOT Analysis

9.17. Sylentis

9.17.1. Company Basic Information and Sales Area

9.17.2. Main Business/Business Overview

9.17.3. Product Portfolio

9.17.4. Financial

9.17.5. Recent Industry Insights

9.17.6. SWOT Analysis

9.18. Arrowhead

9.18.1. Company Basic Information and Sales Area

9.18.2. Main Business/Business Overview

9.18.3. Product Portfolio

9.18.4. Financial

9.18.5. Recent Industry Insights

9.18.6. SWOT Analysis

9.19. Silence Therapeutics

9.19.1. Company Basic Information and Sales Area

9.19.2. Main Business/Business Overview

9.19.3. Product Portfolio

9.19.4. Financial

9.19.5. Recent Industry Insights

9.19.6. SWOT Analysis

9.20. Dicerna

9.20.1. Company Basic Information and Sales Area

9.20.2. Main Business/Business Overview

9.20.3. Product Portfolio

9.20.4. Financial

9.20.5. Recent Industry Insights

9.20.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Oligonucleotide-based Therapy Medicinal Product Market

Figure 4: Global Oligonucleotide-based Therapy Medicinal Product Market: Drivers

Figure 5: Global Oligonucleotide-based Therapy Medicinal Product Market: Challenges

Figure 6: Global Oligonucleotide-based Therapy Medicinal Product Market: Trends

Figure 7: Global Oligonucleotide-based Therapy Medicinal Product Market: Opportunity

Figure 8: Global Oligonucleotide-based Therapy Medicinal Product Market: Restraint

Figure 9: Global Oligonucleotide-based Therapy Medicinal Product Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Oligonucleotide-based Therapy Medicinal Product Market Value (USD Million) By Region

Figure 15: Global Oligonucleotide-based Therapy Medicinal Product Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Oligonucleotide-based Therapy Medicinal Product Market Value (USD Million) By Region

Figure 23: Global Oligonucleotide-based Therapy Medicinal Product Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

93 items

Table 1: Market Segmentation Analysis

Table 2: Global Oligonucleotide-based Therapy Medicinal Product Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Oligonucleotide-based Therapy Medicinal Product Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Oligonucleotide-based Therapy Medicinal Product Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Oligonucleotide-based Therapy Medicinal Product Market Value (USD Million) By Region

Table 10: Global Oligonucleotide-based Therapy Medicinal Product Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Oligonucleotide-based Therapy Medicinal Product Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Oligonucleotide-based Therapy Medicinal Product Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Oligonucleotide-based Therapy Medicinal Product Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Sarepta Therapeutics Basic Information And Sales Area

Table 31: Sarepta Therapeutics. Products Portfolio

Table 32: Ionis Pharmaceuticals Basic Information And Sales Area

Table 33: Ionis Pharmaceuticals. Products Portfolio

Table 34: Alnylam Basic Information And Sales Area

Table 35: Alnylam. Products Portfolio

Table 36: Biogen Basic Information And Sales Area

Table 37: Biogen. Products Portfolio

Table 38: Nippon Shinyaku Basic Information And Sales Area

Table 39: Nippon Shinyaku. Products Portfolio

Table 40: Sobi Basic Information And Sales Area

Table 41: Sobi. Products Portfolio

Table 42: Novartis Basic Information And Sales Area

Table 43: Novartis. Products Portfolio

Table 44: BioNTech Basic Information And Sales Area

Table 45: BioNTech. Products Portfolio

Table 46: Pfizer Basic Information And Sales Area

Table 47: Pfizer. Products Portfolio

Table 48: Moderna Therapeutics Basic Information And Sales Area

Table 49: Moderna Therapeutics. Products Portfolio

Table 50: Jazz Pharmaceuticals Basic Information And Sales Area

Table 51: Jazz Pharmaceuticals. Products Portfolio

Table 52: CureVac Basic Information And Sales Area

Table 53: CureVac. Products Portfolio

Table 54: Regulus Therapeutics Basic Information And Sales Area

Table 55: Regulus Therapeutics. Products Portfolio

Table 56: ProQR Basic Information And Sales Area

Table 57: ProQR. Products Portfolio

Table 58: Secarna Basic Information And Sales Area

Table 59: Secarna. Products Portfolio

Table 60: MiNA Therapeutics Basic Information And Sales Area

Table 61: MiNA Therapeutics. Products Portfolio

Table 62: Sylentis Basic Information And Sales Area

Table 63: Sylentis. Products Portfolio

Table 64: Arrowhead Basic Information And Sales Area

Table 65: Arrowhead. Products Portfolio

Table 66: Silence Therapeutics Basic Information And Sales Area

Table 67: Silence Therapeutics. Products Portfolio

Table 68: Dicerna Basic Information And Sales Area

Table 69: Dicerna. Products Portfolio

Table 70: Global Market Value (USD Million) (2025-2032) By Application

Table 71: Global Market Share (%) By Application (2032)

Table 72: Global Market Value (USD Million) (2025-2032) By Types

Table 73: Global Market Share (%) By Types (2032)

Table 74: Global Oligonucleotide-based Therapy Medicinal Product Market Value (USD Million) By Region

Table 75: Global Oligonucleotide-based Therapy Medicinal Product Market Share (%) By Region (2025-2032)

Table 76: North America Market Value (USD Million) (2025-2032) By Country

Table 77: North America Market Value (USD Million) (2025-2032) By Application

Table 78: North America Market Value (USD Million) (2025-2032) By Types

Table 79: Europe Market Value (USD Million) (2025-2032) By Country

Table 80: Europe Market Value (USD Million) (2025-2032) By Application

Table 81: Europe Market Value (USD Million) (2025-2032) By Types

Table 82: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 83: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 84: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 85: South America Market Value (USD Million) (2025-2032) By Country

Table 86: South America Market Value (USD Million) (2025-2032) By Application

Table 87: South America Market Value (USD Million) (2025-2032) By Types

Table 88: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 89: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 90: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 91: Research Programs/Design For This Report

Table 92: Key Data Information From Secondary Sources

Table 93: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Oligonucleotide-based Therapy Medicinal Product Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	12.49 billion
Revenue forecast in 2033	21.78 billion
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Sarepta Therapeutics; Ionis Pharmaceuticals; Alnylam; Biogen; Nippon Shinyaku; Sobi; Novartis; BioNTech; Pfizer; Moderna Therapeutics; Jazz Pharmaceuticals; CureVac; Regulus Therapeutics; ProQR; Secarna; MiNA Therapeutics; Sylentis; Arrowhead; Silence Therapeutics; Dicerna
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Restraints2 items

Opportunities2 items

Challenges2 items

Market Segmentation

Loading chart…

Oligonucleotide-based Therapy Medicinal Product Segmentation Breakdown9 items

Application

Neuromuscular Diseases

hATTR

COVID-19

Other

Types

Antisense Oligonucleotides (ASO)

siRNA

mRNA

Regional Insights

Loading chart…

Competitive Landscape

Sarepta Therapeutics: regional expansion

Ionis Pharmaceuticals: innovation pipeline

Alnylam: premium pricing

Biogen: vertical integration

Nippon Shinyaku: local manufacturing

Sobi: OEM tie-ups

Key Oligonucleotide-based Therapy Medicinal Product Companies20 items

Sarepta Therapeutics

Ionis Pharmaceuticals

Alnylam

Biogen

Nippon Shinyaku

Sobi

Novartis

BioNTech

Pfizer

Moderna Therapeutics

Jazz Pharmaceuticals

CureVac

Regulus Therapeutics

ProQR

Secarna

MiNA Therapeutics

Sylentis

Arrowhead

Silence Therapeutics

Dicerna

Market Ecosystem

Raw material/component suppliers — provide nucleotides and reagents

Technology providers — develop synthesis and manufacturing technologies

OEMs / manufacturers — produce oligonucleotide-based therapies

System integrators / EPCs — formulate and package final products

Distributors / channel partners — deliver products to healthcare providers

Regulators/standards bodies — oversee safety and efficacy standards

End users / buyers — healthcare providers and patients

Recent Industry Insights

Analyst Overview

Table of Contents